1. Pink Sheet
  2. >>Archive

Orexigen Insists It Can Grow Contrave After Takeda Exit

 
• By Lisa LaMotta

Beware the Ides of March, especially if you're an investor in the obesity drug market. Orexigen added further evidence that the market is crumbling as it hitched its wagon to a partner that is even worse off.

Orexigen did its best to put a positive spin on its big pharma partner Takeda Pharmaceutical Co. Ltd. exiting the alliance for Contrave, and announced a smaller partnership with Valeant Pharmaceuticals International Inc. in hopes of distracting from the news. Yet, investors remain unenthused by the biotech's new strategy for its obesity drug.

The La Jolla, Calif. biotech announced March 15 that its Japanese pharma partner Takeda would be returning the rights to its obesity drug Contrave (naltrexone/bupropion), ending a five-plus year partnership

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet

Austria To Fine Companies For Violating New Drug Stockpiling Rule

 
• By Neena Brizmohun

A new ordinance for addressing drug shortages in Austria requires drug companies distributing any of the hundreds of products listed in an accompanying annex to maintain adequate stock in the country to meet patient demand for four months.

EMA Explores Using AI Language Models To Refine Oncology Guidance

 
• By Vibha Sharma

The European Medicines Agency has for the first time explicitly stated it is considering the use of large language models as a tool to improve the readability of a scientific guideline.

Industry On Making England’s HTA Innovation Lab A Success

 
• By Eliza Slawther

England’s health technology assessment institute, NICE, must ensure that there is clarity for manufacturers on how its methods and processes might change following testing in its sandbox environment, the Association of the British Pharmaceutical Industry said.